Use of COVID-19 Vaccines in the United States
Interim Clinical Considerations
Summary of recent changes (last updated April 21, 2022):
- Added considerations for the option to receive a second COVID-19 vaccine booster dose
- Updated guidance for COVID-19 vaccination after SARS-CoV-2 infection
Get Email Updates
Receive email updates about this page.
COVID-19 Vaccines, Recommendations, and Schedule
Special Situations and Populations
Appendices
- People who received COVID-19 vaccine outside the United States (Appendix A)
- People who received COVID-19 vaccine as part of a clinical trial (Appendix B)
- Vaccine administration errors and deviations (Appendix C)
- Guidance for people who are moderately or severely immunocompromised and vaccinated with Janssen COVID-19 vaccine (Appendix D)
- Triage of people with a history of allergies or allergic reactions (Appendix E)
- Ingredients included in COVID-19 vaccines (Appendix F)
More about the Interim Clinical Considerations
See the FAQ page for answers to commonly asked questions about the Interim Clinical Considerations.
Page last reviewed: March 30, 2022
Content source: National Center for Immunization and Respiratory Diseases